REYPOINT
LIVE

Serial Number

90844780

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Jul 23, 2021

Add to watchlist:

No watchlists yet
View on USPTO

REYPOINT Trademark

Serial Number: 90844780

REYPOINT is a trademark filed by Bristol-Myers Squibb Company on July 23, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Bristol-Myers Squibb Company (20 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

July 23, 2021

Registration Date

Not Registered

Published for Opposition

February 21, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 18, 2026 EXRA
SOU EXTENSION 5 GRANTED
Feb 17, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 11, 2026 AITU
SOU TEAS EXTENSION RECEIVED
Sep 24, 2025 EEXT
SOU EXTENSION 5 FILED
Sep 23, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 8, 2025 EXRA
SOU EXTENSION 4 GRANTED
Apr 7, 2025 EX4G
SOU EXTENSION 4 FILED
Apr 7, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 7, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 15, 2024 EXRA
SOU EXTENSION 3 GRANTED
Oct 15, 2024 EX3G
SOU EXTENSION 3 FILED
Oct 15, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 15, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 15, 2024 EXRA
SOU EXTENSION 2 GRANTED
Mar 14, 2024 EX2G
SOU EXTENSION 2 FILED
Mar 14, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 5, 2023 EXRA
SOU EXTENSION 1 GRANTED
Oct 3, 2023 EX1G
SOU EXTENSION 1 FILED
Oct 3, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 3, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 18, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 21, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 21, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 1, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 18, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 11, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 11, 2023 CRFA
ASSIGNED TO LIE
Jan 11, 2023 ALIE
NOTICE OF REVIVAL - E-MAILED
Nov 15, 2022 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 14, 2022 TROA
PETITION TO REVIVE-GRANTED
Nov 14, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Nov 14, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Nov 9, 2022 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Nov 9, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Nov 9, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 26, 2022 GNRN
NON-FINAL ACTION E-MAILED
Apr 26, 2022 GNRT
NON-FINAL ACTION WRITTEN
Apr 26, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 19, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 23, 2021 NWOS
NEW APPLICATION ENTERED
Jul 27, 2021 NWAP